Abstract:In this study library of bisubstarte analogues, uridine‐mimetic peptide conjugates are designed, synthesised and evaluated for their O‐linked β‐N‐acetylglucosamine transferase (OGT) inhibition activity. In this approach uridine diphosphate moiety from sugar donor UDP‐GlcNAc is replaced with quinolinone‐6‐sulfonamide (Q6S) or quinolone‐4‐carboxamide (Q4 C). OGT inhibition assay suggested that bisubstarte analogues have retained OGT inhibition and enzyme inhibition is peptide sequence dependent. Our finding demonstrates that replacement of charged nucleotide with quinolinone heterocycles will aid development of cell‐permeable OGT inhibitors in the future. O‐linked β‐N‐acetylglucosamine transferase (OGT) is the pivotal mammalian enzyme that serves as a nutrient sensor, linking metabolic status to diverse cellular signalling pathways by catalyzing N‐acetylglucosamine transfer to various proteins and detects fluctuations in UDP‐GlcNAc concentrations. Increased UDP‐GlcNAc levels induce O‐GlcNAcylation of proteins, influencing the stability and localization of biomolecules, including transcription factors, kinases, phosphatases, tumour suppressors, and histone‐modifying proteins. Dysregulation and excessive OGT expression can adversely impact cellular processes. The lack of potent and selective inhibitors for OGT has impeded the progress in understanding the enzyme and its molecular mechanisms. This research article details the successful development and synthesis of a series of bisubstrate analogue inhibitors, specifically focusing on inhibiting the O‐GlcNAc transferase (OGT) enzyme. Compound 29 emerged as a promising inhibitor, demonstrating an IC50 value of 134.40 μM in in‐vitro assays. The study emphasizes the crucial role of the acceptor substrate analogue in bisubstrate inhibitor design, highlighting its equal importance alongside the donor substrate analogue. While donor substrate mimetics alone exhibited limited inhibition, their conjugation with appropriate peptides significantly enhanced the overall potency of the final bisubstrate inhibitor. Particularly, peptide derivatives proved superior as acceptor substrate analogues compared to normal substrate peptides. Preliminary data suggest the potential of uridine‐mimetics, like Q6S and Q4 C, following scaffold structure refinement. In‐silico predictions propose that replacing pyrophosphate with a flexible linker substantially improves physicochemical properties relevant to cell permeation. This comprehensive investigation offers valuable insights into designing and optimizing bisubstrate analogue inhibitors for OGT, revealing potential avenues for further refinement and development.

Identification of a Polypeptide Inhibitor of O -GlcNAc Transferase with Picomolar Affinity

Spatiotemporal Activation of Protein O-GlcNAcylation in Living Cells.

An Isotope-Coded Photocleavable Probe for Quantitative Profiling of Protein O-GlcNAcylation

Elucidating the protein substrate recognition of O-GlcNAc transferase (OGT) toward O-GlcNAcase (OGA) using a GlcNAc electrophilic probe

Inhibition of O-GlcNAc Transferase (OGT) by Peptidic Hybrids.

Photoactivatable O‐GlcNAc transferase library enables covalent chemical capture of solvent‐exposed TPR domain interactions

C-Terminal Tag Location Hampers in Vitro Profiling of OGT Peptide Substrates by Mrna Display

Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray

Motif-dependent binding on the intervening domain regulates O-GlcNAc transferase

Virtual Screening of Human O-Glcnac Transferase Inhibitors

Recognition of a glycosylation substrate by the O-GlcNAc transferase TPR repeats

Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors Via Tethering in Situ Click Chemistry.

Homology between O-linked GlcNAc transferases and proteins of the glycogen phosphorylase superfamily

Bisubstrate Uridine‐Mimetic‐Peptide Conjugates as O‐GlcNAc Transferase (OGT) Inhibitors

The Synthesis and Characterization of a Helical Miniature Protein Mimicking the OGT Active Domain

Amino acid tethered benzoxazolone as highly potent inhibitors of O-glycosylation

Opportunities for Therapeutic Modulation of O-GlcNAc

Production of Glycopeptide Derivatives for Exploring Substrate Specificity of Human OGA Toward Sugar Moiety

Discovery of two non-UDP-mimic inhibitors of O-GlcNAc transferase by screening a DNA-encoded library

Multi-comparative Thermal Proteome Profiling Uncovers New O-GlcNAc Proteins in a System-wide Method

Identification of a Diketopiperazine-Based O-GlcNAc Transferase Inhibitor Sensitizing Hepatocellular Carcinoma to CDK9 Inhibition.